scispace - formally typeset
M

Mohan Viswanathan

Researcher at Massachusetts Institute of Technology

Publications -  7
Citations -  1995

Mohan Viswanathan is an academic researcher from Massachusetts Institute of Technology. The author has contributed to research in topics: Sirtuin & Unfolded protein response. The author has an hindex of 6, co-authored 7 publications receiving 1755 citations.

Papers
More filters
Journal ArticleDOI

The NAD+/Sirtuin Pathway Modulates Longevity through Activation of Mitochondrial UPR and FOXO Signaling

TL;DR: The data suggest that augmenting mitochondrial stress signaling through the modulation of NAD(+) levels may be a target to improve mitochondrial function and prevent or treat age-associated decline.
Journal ArticleDOI

A Role for SIR-2.1 Regulation of ER Stress Response Genes in Determining C. elegans Life Span

TL;DR: These findings demonstrate that abu-11 and other members of its ER stress gene family are positive determinants of C. elegans life span and that resveratrol extends life span by inhibiting sir-2.1-mediated repression of ER stress genes.
Journal ArticleDOI

C. elegans SIR-2.1 Interacts with 14-3-3 Proteins to Activate DAF-16 and Extend Life Span

TL;DR: The existence of a stress-dependent pathway in which SIR-2.1 and 14-3-3 act in parallel to the insulin-like pathway to activate DAF-16 and extend life span is proposed.
Journal ArticleDOI

Regulation of Caenorhabditis elegans lifespan by sir-2.1 transgenes

TL;DR: The first metazoan Sir2 homologue shown to affect lifespan, Caenorhabditis elegans sir-2.1, was identified and the extension of lifespan was overestimated in a high-copy sir- 2.1 transgene-containing worm strain because of an unlinked mutation.
Journal ArticleDOI

A novel Caenorhabditis elegans allele smn-1(cb131), mimicking a mild form of spinal muscular atrophy, provides a convenient drug screening platform highlighting new and pre-approved compounds

TL;DR: The isolation and characterization of smn-1(cb131), a novel allele encoding a substitution in a highly conserved residue of exon 2, resembling a point mutation found in a patient with type IIIb SMA is reported, which may assist in accelerating the development of drugs for the treatment of SMA.